GE Healthcare Technologies Inc

Aktienanalyse zu GE Healthcare Technologies Inc (GEHC)

$69.570

-0.772 (-1.11%)Zum Schluss

Loading chart…
Hoch
71.320
Eröffnung
71.100
Volumengewichteter Durchschnittskurs
70.11
Volumen
3.12M
Marktkap.
35.98B
Tief
69.450
Umsatz
218.45M
EV/EBITDA, TTM
9.91

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

KI-Analyse of GE Healthcare Technologies Inc (GEHC)

Kaufen

GE Healthcare Technologies Inc is a good buy right now due to its current price of $65.74, which is below the analyst price targets of $85 and $93 from Barclays and Needham, respectively. The company has shown a positive trend with a 5-day change of +2.26% and a recent dividend increase of 14%, reflecting strong financial health. However, the main risk is the year-to-date change of -20.62%, indicating potential volatility in the stock's performance.

Bewertungskennzahlen

Das aktuelle erwartete KGV von GE Healthcare Technologies Inc (GEHC) beträgt 12.12, verglichen mit dem 5-Jahres-Durchschnitt von 17.48.

Erwartetes KGV

Stark unterbewertet
5J-Durchschnitt P/E
17.48
Aktuelles P/E
12.12
Überbewertet
19.91
Unterbewertet
15.05

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
11.34
Aktuelles EV/EBITDA
9.91
Überbewertet
12.85
Unterbewertet
9.83

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
1.67
Aktuelles P/S
1.40
Überbewertet
1.95
Unterbewertet
1.40

Alphio-AI-Kursszenarien für GEHC

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%GEHC

$83.18

Szenariopreis

B

Basis

Basis · 50%GEHC

$81.20

Szenariopreis

B

Bärisch

Bärisch · 25%GEHC

$74.35

Szenariopreis

Whales, die GEHC halten

H

Hotchkis and Wiley Capital Management, LLC

+ HältGEHC

+9.19%

3-Monats-Rendite

N

NewEdge Advisors, LLC

+ HältGEHC

+6.00%

3-Monats-Rendite

B

Barrow, Hanley, Mewhinney & Strauss, LLC

+ HältGEHC

+5.18%

3-Monats-Rendite

S

Salem Investment Counselors, Inc.

+ HältGEHC

+4.26%

3-Monats-Rendite

L

Letko, Brosseau & Associates Inc.

+ HältGEHC

+4.14%

3-Monats-Rendite

D

Dodge & Cox

+ HältGEHC

+2.61%

3-Monats-Rendite

Event-Zeitleiste

2026-10-16 (ET)

09:30:00

GE HealthCare Publishes Anesthesia Study from University of Michigan

2026-10-15 (ET)

08:30:00

GE HealthCare Announces MINItrace Magni Achieves CE Mark

2026-10-05 (ET)

16:30:00

Nasdaq Rises Nearly 300 Points as Market Digests Jobs Report

12:30:00

Nasdaq Rises Nearly 200 Points, Led by Tech Stocks

08:30:00

GE HealthCare Acquires SOFIE Biosciences for $945M

News

GEHC FAQ – beantwortet von Alphio AI

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

GE Healthcare Technologies Inc is a good buy right now due to its current price of $65.74, which is below the analyst price targets of $85 and $93 from Barclays and Needham, respectively. The company has shown a positive trend with a 5-day change of +2.26% and a recent dividend increase of 14%, reflecting strong financial health. However, the main risk is the year-to-date change of -20.62%, indicating potential volatility in the stock's performance.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln